NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Neuromyelitis optica
- Focus Therapeutic Use
- Sponsors Nihon Pharmaceutical
- 11 Apr 2017 Status changed from recruiting to completed.
- 11 Jun 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 11 Jun 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov.